Tempest Therapeutics faces Nasdaq delisting over stockholders' equity shortfall
TPST•Tempest Therapeutics received a Nasdaq delisting notice on November 17, 2026, after failing to meet the exchange’s $2.5 million minimum stockholders’ equity requirement. The company plans to appeal; a timely hearing request would stay delisting while the appeal proceeds.
1. Delisting notice
Nasdaq notified Tempest Therapeutics on November 17, 2026, that it faced delisting after the company failed to regain compliance with minimum stockholders’ equity requirements. Its stockholders’ equity was below $2.5 million as of March 31, 2026, violating Nasdaq Listing Rule 5550(b)(1).
2. Appeal planned
Tempest did not complete a required capital-raising transaction by the extended November 16 compliance deadline. The company plans to appeal, and a timely hearing request would stay delisting, allowing its common stock to continue trading on the Nasdaq Capital Market.




